22 hours Ago By Defense World Staff
Renaissance Technologies LLC trimmed its position in Nevro Corp. ( NYSE:NVRO – Free Report ) by 5.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 300,309 shares of the medical equipment provider’s stock after selling 16,610 shares during the period. Renaissance Technologies LLC owned approximately 0.80% of Nevro worth $1,117,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of NVRO. Prudential Financial Inc. boosted its holdings in shares of Nevro by 243.
4% in the fourth quarter. Prudential Financial Inc. now owns 195,680 shares of the medical equipment provider’s stock valued at $728,000 after acquiring an additional 138,700 shares in the last quarter.
Amundi purchased a new stake in Nevro in the 4th quarter valued at approximately $30,000. Virtu Financial LLC increased its position in Nevro by 59.9% during the 4th quarter.
Virtu Financial LLC now owns 17,956 shares of the medical equipment provider’s stock worth $67,000 after purchasing an additional 6,725 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Nevro by 62.
3% during the 4th quarter. PNC Financial Services Group Inc. now owns 20,548 shares of the medical equipment provider’s stock worth $76,000 after buying an additional 7,889 shares in the last quarter.
Finally, Sei Investments Co. acquired a new stake in shares of Nevro in the 4th quarter valued at approximately $77,000. 95.
52% of the stock is owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades Several research analysts have issued reports on the company. Canaccord Genuity Group increased their price objective on Nevro from $4.
00 to $5.85 and gave the stock a “hold” rating in a research report on Friday, February 7th. Jefferies Financial Group upgraded shares of Nevro from an “underperform” rating to a “hold” rating and increased their price target for the company from $4.
50 to $5.85 in a report on Monday, February 10th. Piper Sandler raised shares of Nevro from a “neutral” rating to an “overweight” rating and dropped their target price for the company from $6.
00 to $5.85 in a report on Friday, February 7th. Finally, StockNews.
com assumed coverage on Nevro in a research note on Wednesday, April 23rd. They set a “hold” rating on the stock. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company’s stock.
According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.36.
Nevro Trading Up 0.1 % Nevro stock opened at $5.85 on Wednesday.
The stock has a market cap of $224.32 million, a PE ratio of -3.09 and a beta of 0.
81. The company has a current ratio of 5.02, a quick ratio of 3.
76 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $5.
81 and a 200 day moving average price of $5.06. Nevro Corp.
has a 52 week low of $3.17 and a 52 week high of $11.79.
Nevro ( NYSE:NVRO – Get Free Report ) last announced its quarterly earnings data on Tuesday, March 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.
79) by $0.15. The business had revenue of $105.
55 million for the quarter, compared to the consensus estimate of $102.61 million. Nevro had a negative net margin of 16.
54% and a negative return on equity of 23.52%. Equities research analysts predict that Nevro Corp.
will post -2.44 earnings per share for the current fiscal year. About Nevro ( Free Report ) Nevro Corp.
, a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. Featured Articles Five stocks we like better than Nevro The Most Important Warren Buffett Stock for Investors: His Own Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Which Wall Street Analysts are the Most Accurate? Coca-Cola Company Stock Can Bubble to New Highs This Year Technology Stocks Explained: Here’s What to Know About Tech 3 Stocks Lifting 2025 Guidance Despite Market Jitters Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.
com's FREE daily email newsletter ..
